grant
Discovery of Chemical Factors in the Gut Microbiome that Control Alpha-Synuclein Aggregation in Parkinson's Disease
Organization UNIVERSITY OF CALIFORNIA-IRVINELocation IRVINE, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY2025AddressAffectAlimentary CanalAnimalsBiochemicalBody TissuesBrainBrain Nervous SystemC elegansC. elegansC.elegansCaenorhabditis elegansCell BodyCellsChemicalsClinical TrialsCo-cultureCocultivationCocultureCoculture TechniquesCranial Nerve XDNA Molecular BiologyDietDigestive TractDisciplineDiseaseDisease ProgressionDisorderDopamineE coliE. coliEarly InterventionEcologic SystemsEcological SystemsEcosystemEncephalonEnteralEntericEnteroendocrine CellEpithelial CellsEscherichia coliFe elementGI TractGI microbiomeGI microbiotaGastrointestinal TractGastrointestinal microbiotaGastrointestinal tract structureGeneticHumanHydroxytyramineIn VitroInitiation FactorsIntestinalIntestinesIronKnowledgeLearningMapsMediatingMethodsMicrobiologyMissionModelingModern ManMolecularMolecular BiologyNAC precursorNO3-National Institutes of HealthNerve CellsNerve DegenerationNerve UnitNervous System DiseasesNervous System DisorderNeural CellNeurocyteNeurologic DisordersNeurological DisordersNeuron DegenerationNeuronsNitratesNitritesOrganometallic ChemistryOxidantsOxidation-ReductionOxidative StressOxidizing AgentsPARK1 proteinPARK4 proteinParalysis AgitansParkinsonParkinson DiseasePeptide Initiation FactorsPersonsPhysiologicPhysiologicalPhysiologyPlayPneumogastric NervePrimary ParkinsonismProcessProteomicsPublic HealthQualifyingRedoxReporterResearchRespirationRoleSNCASNCA proteinSourceSystemTenth Cranial NerveTestingTimeTissuesTranslation Initiation FactorTranslational Initiation FactorUnited States National Institutes of HealthVagus NerveVagus nerve structureWorka-syna-synucleinalimentary tractalpha synucleinalpha synuclein genealphaSP22asynbacteria in the gutbowelclinical relevanceclinical translationclinically relevantclinically translatabledevelop therapydiagnostic biomarkerdiagnostic markerdietsdigestive canaldigestive tract microbiomedisabilityelectron acceptorenteric microbial communityenteric microbiomeenteric microbiotaexperimentexperimental researchexperimental studyexperimentsgastrointestinalgastrointestinal microbial floragastrointestinal microbiomegut bacteriagut communitygut floragut microbe communitygut microbesgut microbial communitygut microbial compositiongut microbial consortiagut microbial speciesgut microbiomegut microbiotagut microbioticgut microfloragut-associated microbiomeinnovateinnovationinnovativeinsoluble aggregateintervention developmentintestinal biomeintestinal epitheliumintestinal floraintestinal microbesintestinal microbiomeintestinal microbiotaintestinal microfloraintestinal tract microfloramicrobialmicrobial consortiamicrobial floramicrobiome community compositionmicrobiome compositionmicrobiome species compositionmicrobiome structuremicrobiotamicrofloramonomermotor diseasemotor disordermotor dysfunctionmotor impairmentmouse modelmovement impairmentmovement limitationmultispecies consortiamurine modelneural degenerationneurodegenerationneurodegenerativeneurological degenerationneurological diseaseneuronalneuronal degenerationnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnitratenon A-beta component of AD amyloidnon A4 component of amyloid precursornovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoxidation reduction reactionpreventpreventingprotein aggregateprotein aggregationrespiratory mechanismresponsesocial roletherapeutic candidatetherapeutic targettherapy developmenttooltreatment developmentα synuclein geneα-synα-synuclein
Description preview
PROJECT SUMMARY. Accumulation of α-synuclein (α-syn) protein aggregates in brain neurons is thought to
play a causal role in Parkinson's disease (PD). There is mounting evidence that the gut is a source of α-syn
aggregates in the brain; however, the factors involved remain incompletely understood, limiting development of
treatments to prevent PD.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click